TURNING CUTTING-EDGE INNOVATIONS
INTO BREAKTHROUGH BIOTECH COMPANIES

Argobio is a startup studio dedicated to therapeutics based in Paris launched in March 2021 with 50 M€ funding.

 

Our goal is to build high-potential innovative biotech companies up to Series A financing, based on promising research projects.
 

Argobio provides
financial support and operational excellence to early stage projects :
    

Select early-stage cutting-edge innovations from European academia
 

Structure a collaboration agreement with the research institute
 

Provide financial support and a team of experienced scientists and entrepreneurs to mature the project
 

Create new companies during the incubation phase  


INVESTORS

Argobio is sponsored by 5 complementary investors.


PORTFOLIO

Argobio has built a pipeline of projects
reflecting the diversity of therapeutic indications
and modalities interest. 

OUR TEAM

Argobio has assembled an experienced team
with track-record in science and entreneurship. 

Our latest news

See all our news